Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Novartis AG (NOVN) Receives a Hold from Barclays

Tipranks - Tipranks - Sat Mar 28, 4:48AM CDT

Barclays analyst James Gordon CFA maintained a Hold rating on Novartis AG today and set a price target of CHF120.00.

Claim 30% Off TipRanks Premium

According to TipRanks, Gordon CFA is a 3-star analyst with an average return of 5.3% and a 48.28% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Galderma Group AG.

In addition to Barclays, Novartis AG also received a Hold from UBS’s Matthew Weston in a report issued on March 23. However, yesterday, Morgan Stanley assigned a Buy rating to Novartis AG (Six Swiss: NOVN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).